Vericel Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
61.0%projected annual EPS growth
Analyst Coverage
7analysts covering
FY Revenue (est.)
$336.2Mnext fiscal year
FY EPS (est.)
$0.52next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
MACI Biopsy Volume Growth QuarterlyTarget: Double-digit growth
MACI Implant Volume Growth QuarterlyTarget: Double-digit growth
MACI Arthro Trained Surgeons QuarterlyTarget: Continued expansion
Prior Authorization Approval Rate AnnuallyTarget: 90-95%
Watch Items
- Burlington Manufacturing Facility Commercial Scale-upTrigger: Delays in commercial production runs or yield issues in Q2 2026 and beyondAction: Assess impact on MACI gross margins and capacity constraints for peak season (Q4)
- U.K. MHRA Regulatory Submission for MACITrigger: Failure to submit Marketing Authorization Application (MAA) by end of 2026Action: Re-evaluate international expansion timeline and 2027 launch projections
- NexoBrid BARDA Contract ExecutionTrigger: H2 2026 procurement revenue falling below the expected $5M-$6M rangeAction: Review BARDA delivery milestones and room-temperature formulation development progress
Research as of 20 Jun 2026